Get the Stockscreener App
30.75
0.65%
-0.20
After Hours:
30.83
0.08
+0.26%
Royalty Pharma Plc Stock (RPRX) Forecast
The Royalty Pharma Plc (RPRX) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $24.83, representing a -19.24% decrease from the current price of $30.75. The highest analyst price target is $29.38, and the lowest is $20.29.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RPRX Price Target
Average 23.19
(-24.59% Downside)
Is Royalty Pharma Plc (RPRX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 82.15 | Sell |
| STOCH(9,6) | 92.32 | Sell |
| STOCHRSI(14) | 92.37 | Sell |
| MACD(12,26) | 1.2768 | Buy |
| ADX(14) | 35.22 | Buy |
| William %R | -5.753 | Sell |
| CCI(14) | 115.74 | Buy |
Buy: 3
Sell: 4
Neutral: 0
Summary: Sell
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
28.58
Buy
|
29.05
Buy
|
| MA20 |
26.87
Buy
|
27.79
Buy
|
| MA50 |
26.38
Buy
|
26.95
Buy
|
| MA100 |
27.16
Buy
|
27.00
Buy
|
| MA200 |
27.34
Buy
|
27.33
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, RPRX could be considered a Strong Buy, with 17 technical analysis indicators signaling 13 Buy signals, 4 signaling Sell signals and 0 Neutral signals. This might be a good time to open fresh positions on RPRX, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 82.15 indicates that RPRX is overbought. This suggests that RPRX price has experienced a significant increase over a specified lookback period, potentially leading to a correction.
- STOCH (Stochastic Oscillator): The STOCH value of 92.32 indicates that RPRX is oversold. This means that RPRX price is at or near the highest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 92.37 indicates that RPRX is oversold. This suggests that RPRX price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 35.22 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 115.74 indicates that RPRX is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term RPRX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Royalty Pharma Plc financial reports and earnings history, Royalty Pharma Plc (RPRX) stock could reach $3.4563 by 2030, $20.94 by 2040 and $52.64 by 2050. See the projected annual prices until 2050 of the Royalty Pharma Plc stock below:
- Royalty Pharma Plc (RPRX) is expected to reach an average price of $12.71 in 2035, with a high prediction of $12.13 and a low estimate of $12.40. This indicates an $-58.67% rise from the last recorded price of $30.75.
- Royalty Pharma Plc (RPRX) stock is projected to chart a bullish course in 2040, with an average price target of $21.44, representing an $-30.28% surge from its current level. The forecast ranges from a conservative $20.32 to a sky-high $20.94.
- Our analysts predict Royalty Pharma Plc (RPRX) to jump 30.93% by 2045, soaring from $37.86 to an average price of $40.26, potentially reaching $37.68. While $37.86 is the low estimate, the potential upside is significant.
- Royalty Pharma Plc (RPRX) stock is expected to climb by 2050, reaching an average of $54.47, a $77.14% jump from its current level. However, a wide range of estimates exists, with high and low targets of $52.64 and $51.50, respectively, highlighting the market's uncertainty.
Royalty Pharma Plc Stock (RPRX) Year by Year Forecast
Royalty Pharma Plc Stock (RPRX) Price Forecast for 2025
Royalty Pharma Plc Stock (RPRX) is expected to reach an average price of $25.27 in 2025, with a high prediction of $33.66 and a low estimate of $16.88. This indicates an -17.81% fall from the last recorded price of $30.75.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| February, 2025 | $27.62 | $20.29 | $29.38 | -10.17% |
| March, 2025 | $23.87 | $22.34 | $29.49 | -22.38% |
| April, 2025 | $22.02 | $21.36 | $26.62 | -28.38% |
| May, 2025 | $26.42 | $20.40 | $26.59 | -14.09% |
| June, 2025 | $22.35 | $22.08 | $28.35 | -27.31% |
| July, 2025 | $19.76 | $19.36 | $24.33 | -35.75% |
| August, 2025 | $20.90 | $17.19 | $21.74 | -32.02% |
| September, 2025 | $20.37 | $19.55 | $21.88 | -33.76% |
| October, 2025 | $20.47 | $16.88 | $20.54 | -33.42% |
| November, 2025 | $24.14 | $18.32 | $24.54 | -21.50% |
| December, 2025 | $20.18 | $19.75 | $25.94 | -34.36% |
Royalty Pharma Plc Stock (RPRX) Price Forecast for 2026
The predicted value for Royalty Pharma Plc (RPRX) in 2026 is set at an average of $23.85. Estimates vary from a peak of $28.67 to a trough of $19.03, indicating an -22.45% surge from the present price of $30.75.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $22.83 | $19.03 | $23.25 | -25.76% |
| February, 2026 | $22.73 | $20.22 | $25.23 | -26.07% |
| March, 2026 | $21.35 | $19.03 | $23.98 | -30.57% |
| April, 2026 | $21.44 | $20.28 | $23.08 | -30.26% |
| May, 2026 | $27.33 | $20.85 | $27.98 | -11.12% |
| June, 2026 | $23.32 | $20.45 | $27.84 | -24.15% |
| July, 2026 | $24.06 | $22.23 | $25.55 | -21.76% |
| August, 2026 | $26.47 | $21.06 | $27.30 | -13.90% |
| September, 2026 | $26.38 | $25.71 | $28.29 | -14.22% |
| October, 2026 | $25.89 | $25.59 | $28.67 | -15.79% |
| November, 2026 | $24.57 | $24.28 | $28.40 | -20.10% |
| December, 2026 | $27.19 | $23.88 | $27.26 | -11.56% |
Royalty Pharma Plc Stock (RPRX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Royalty Pharma Plc (RPRX) is $22.04, with a high forecast of $29.18 and a low forecast of $14.91. This indicates an -28.31% decrease from the last price of $30.75.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $27.46 | $25.92 | $28.56 | -10.70% |
| February, 2027 | $26.50 | $26.49 | $29.18 | -13.84% |
| March, 2027 | $24.31 | $22.83 | $27.65 | -20.95% |
| April, 2027 | $24.05 | $22.72 | $24.35 | -21.77% |
| May, 2027 | $21.10 | $21.00 | $24.23 | -31.38% |
| June, 2027 | $21.47 | $18.05 | $23.63 | -30.16% |
| July, 2027 | $20.75 | $20.57 | $22.26 | -32.52% |
| August, 2027 | $18.14 | $17.78 | $21.40 | -41.02% |
| September, 2027 | $16.90 | $16.63 | $20.52 | -45.04% |
| October, 2027 | $17.30 | $15.19 | $17.61 | -43.75% |
| November, 2027 | $16.73 | $15.93 | $17.77 | -45.59% |
| December, 2027 | $15.65 | $14.91 | $17.25 | -49.12% |
Royalty Pharma Plc Stock (RPRX) Price Forecast for 2028
In 2028, Royalty Pharma Plc (RPRX) is projected to reach an average price of $9.6068, with a high projection of $19.20 and a low estimate of $0.0149. This indicates an -68.76% fall from the last price of $30.75.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $13.61 | $12.45 | $15.91 | -55.74% |
| February, 2028 | $13.64 | $12.91 | $15.20 | -55.65% |
| March, 2028 | $14.03 | $12.95 | $15.31 | -54.37% |
| April, 2028 | $14.67 | $13.84 | $16.71 | -52.31% |
| May, 2028 | $16.42 | $14.05 | $16.85 | -46.60% |
| June, 2028 | $17.39 | $14.78 | $18.32 | -43.46% |
| July, 2028 | $17.99 | $16.84 | $19.20 | -41.49% |
| August, 2028 | $16.04 | $15.69 | $18.54 | -47.85% |
| September, 2028 | $15.78 | $15.10 | $16.45 | -48.69% |
| October, 2028 | $4.1032 | $0.14 | $14.64 | -86.66% |
| November, 2028 | $2.5219 | $0.2613 | $7.331 | -91.80% |
| December, 2028 | $0.4529 | $0.0149 | $5.9897 | -98.53% |
Royalty Pharma Plc Stock (RPRX) Price Forecast for 2029
The 2029 price forecast for Royalty Pharma Plc Stock (RPRX) is $7.1122 on average, with a high prediction of $14.09 and a low estimate of $0.1335. This represents an -76.87% decrease from the previous price of $30.75.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.5316 | $0.3584 | $2.9316 | -95.02% |
| February, 2029 | $1.1875 | $0.9648 | $4.6648 | -96.14% |
| March, 2029 | $0.4535 | $0.1335 | $3.3958 | -98.53% |
| April, 2029 | $2.7545 | $0.5288 | $6.8045 | -91.04% |
| May, 2029 | $12.73 | $2.7822 | $13.58 | -58.59% |
| June, 2029 | $9.0741 | $7.1864 | $14.09 | -70.49% |
| July, 2029 | $8.3251 | $0.9573 | $9.9619 | -72.93% |
| August, 2029 | $4.1038 | $3.1206 | $10.23 | -86.65% |
| September, 2029 | $3.0747 | $2.3215 | $7.637 | -90.00% |
| October, 2029 | $7.3934 | $1.4925 | $9.5934 | -75.96% |
| November, 2029 | $5.0444 | $3.4467 | $7.9591 | -83.60% |
| December, 2029 | $1.3154 | $0.9154 | $5.7721 | -95.72% |
Royalty Pharma Plc Stock (RPRX) Price Forecast for 2030
Royalty Pharma Plc Stock (RPRX) is expected to reach an average price of $5.6302 in 2030, with a high forecast of $11.21 and a low forecast of $0.0522. This signifies an -81.69% decrease from the last price of $30.75.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $2.1541 | $0.4969 | $3.4563 | -92.99% |
| February, 2030 | $0.915 | $0.085 | $3.7473 | -97.02% |
| March, 2030 | $2.536 | $0.0522 | $2.606 | -91.75% |
| April, 2030 | $6.3569 | $0.4615 | $6.7569 | -79.33% |
| May, 2030 | $2.5956 | $2.1479 | $8.1947 | -91.56% |
| June, 2030 | $5.3966 | $1.4834 | $5.7789 | -82.45% |
| July, 2030 | $5.4953 | $2.8999 | $7.8343 | -82.13% |
| August, 2030 | $5.0963 | $1.9085 | $6.6008 | -83.43% |
| September, 2030 | $4.5172 | $3.2717 | $6.1195 | -85.31% |
| October, 2030 | $9.2159 | $3.965 | $11.21 | -70.03% |
| November, 2030 | $6.3669 | $3.8391 | $10.51 | -79.29% |
| December, 2030 | $7.6378 | $5.7596 | $9.1278 | -75.16% |
0.75%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):